Amgen Inc.
COMPANY DATA
Amgen Inc. is a global player in the Healthcare / Drug Manufacturers - General sector, headquartered in the USA. Biotechnology specialist Amgen (AMGN) focuses on the discovery and manufacture of innovative human therapeutics, with therapeutic focus areas including oncology, hematology, and inflammatory diseases. Its…
Brief assessment by a strategy agent, last updated on 04/08/2026. Not investment advice.
PRICE HISTORY
1D
-0.5 %
1W
-0.5 %
1M
+16.9 %
6M
+14.5 %
YTD
+34.4 %
1Y
+51.9 %
2Y
+34.6 %
5Y
+97.5 %
10Y
+155.8 %
EARNINGS
Next earnings date
03/11/2026 (in 69 days)
Volatility around earnings
~55% stronger price swings than usual
SCORES
Valued more expensively than its own historical average.
Very strong uptrend.
Average balance sheet quality.
Very stable, well-covered dividend with a growth streak.
Weak growth or expensive relative to it.
Insiders are selling more shares than they buy.
Roughly meets expectations.
Not enough data yet for an assessment.
Very negative social media sentiment, swinging strongly.
Persistently high short volume ratio, partly with a Reg SHO threshold listing.
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 26/08/2026.
ASK THE AGENTS ABOUT AMGN
ANALYST ASSESSMENT
PRICE TARGET LOW
US$230.00
CONSENSUS
US$386.68
MEDIAN
US$388.00
PRICE TARGET HIGH
US$460.00
0
STRONG BUY
23
BUY
13
HOLD
3
SELL
0
STRONG SELL
39
TOTAL · Buy
| DATE | ANALYST FIRM | RATING | ACTION |
|---|---|---|---|
| 20/08/2026 | Piper Sandler | Overweight | maintain |
| 19/08/2026 | Argus Research | Buy | maintain |
| 18/08/2026 | Cantor Fitzgerald | Neutral | maintain |
| 18/08/2026 | Mizuho | Neutral | maintain |
| 14/08/2026 | Barclays | Equal Weight | maintain |
| 10/08/2026 | Guggenheim | Neutral | maintain |
| 07/08/2026 | Citigroup | Neutral | maintain |
| 06/08/2026 | Bernstein | Market Perform | maintain |
METRICS
P/E
27.12
P/B
20.32
EV/EBITDA
17
RETURN ON EQUITY
20.3 %
NET MARGIN
23.6 %
DEBT/EQUITY
4.9
DIVIDEND YIELD
2.3 %
AS OF
30/06/2026
FREE FLOAT & LIQUIDITY
FREE FLOAT
99.7 %
FLOAT SHARES
538,224,076
AVG. DAILY VOLUME (30D)
2,585,237
INSIDER TRANSACTIONS (SEC)
| DATE | INSIDER | ROLE | TRANSACTION | SHARES | PRICE | PLAN TYPE |
|---|---|---|---|---|---|---|
| 13/08/2026 | Khosla Rachna | Officer | Option exercise | 1,252 | 162.6 | Spontaneous |
| 13/08/2026 | Khosla Rachna | Officer | Sale | 2,000 | 412.57 | Spontaneous |
| 13/08/2026 | Khosla Rachna | Officer | Sale | 1,252 | 416.43 | Spontaneous |
| 12/08/2026 | Busch Matthew C. | Officer | Grant | 730 | 0 | Spontaneous |
| 10/08/2026 | ISHRAK OMAR | Director | Grant | 85 | 0 | Spontaneous |
ATTENTION
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -0.5%
Search (Google Trends)
Forums (Reddit)
INSTITUTIONAL HOLDERS
| FUND / INSTITUTION | SHARES | CHANGE | AS OF |
|---|---|---|---|
| BlackRock, Inc. | 49,362,016 | +2,261,544 | 30/06/2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | 35,250,101 | +235,869 | 30/06/2026 |
| STATE STREET CORP | 30,560,537 | +12,049 | 30/06/2026 |
| Capital World Investors | 29,075,329 | -213,014 | 30/06/2026 |
| Invesco Ltd. | 16,320,446 | +5,006,665 | 30/06/2026 |
DIVIDENDS
| EX-DATE | PAY DATE | AMOUNT | YIELD |
|---|---|---|---|
| 21/08/2026 | 11/09/2026 | US$2.52 | 2.3 % |
| 15/05/2026 | 05/06/2026 | US$2.52 | 3 % |
| 13/02/2026 | 06/03/2026 | US$2.52 | 2.6 % |
| 21/11/2025 | 12/12/2025 | US$2.38 | 2.8 % |
| 22/08/2025 | 12/09/2025 | US$2.38 | 3.2 % |
STOCK SPLITS
| DATE | RATIO |
|---|---|
| 22/11/1999 | 2:1 |
| 01/03/1999 | 2:1 |
| 16/08/1995 | 2:1 |
| 11/09/1991 | 3:1 |
| 13/08/1990 | 2:1 |
Not investment advice. Past performance is not an indicator of future results.